WASHINGTON – A new capital formation environment for small biotechs on their way to going public could be just days away, if the House agrees to the Senate's investor protections for crowd funding. Read More
In the midst of enrolling for a second pivotal Phase III trial of its lead product, dalbavancin, for skin infections, Durata Therapeutics Inc. has filed a registration statement with the SEC for an initial public offering of common stock. Read More
GlaxoSmithKline plc is expected to file for approval of Relovair in both the U.S. and Europe in the middle of this year for chronic obstructive pulmonary disease (COPD), following the completion of the Phase III program. Commercialization of the potentially multi-billion-dollar product could be a boon for long-time partner Theravance Inc. Read More
Researchers have reported that knockout mice lacking either two specific types of major histocompatibility complex molecules or their receptor fared better after a stroke than their wild-type cousins. Read More
• China Biologic Products Inc., of Beijing, said subsidiary Shandong Taibang Biological Products Co. Ltd. received approval from Chinese regulators to begin clinical trials of its human fibrinogen to treat congenital fibrinogen deficiency and acquired fibrinogen deficiency. Read More
• Endocyte Inc., of West Lafayette, Ind., said the World Health Organization and the United States Adopted Names Council approved the nonproprietary name "vintafolide" for ovarian cancer drug EC145 and the nonproprietary name "etarfolatide" for companion imaging agent EC20. Read More
